Violence Against Women in Patients With Alcohol Substance Addiction Training

October 23, 2022 updated by: HUMEYRA HANCER TOK, Abant Izzet Baysal University

The Effect of Creative Drama Training for Alcohol-Substance Addicted Male Patients on Attitudes Towards Violence Against Women: A Randomized Controlled Study

This study was planned as a randomized controlled trial in order to determine the effect of creative drama training for alcohol-substance dependent male patients on their attitudes towards violence against women.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

This study was planned as a randomized controlled trial in order to determine the effect of creative drama training for alcohol-substance dependent male patients on their attitudes towards violence against women.

The study was planned to be fully experimental. The participants to be included in the study will be selected from men who are followed up with a diagnosis of addiction in a mental health hospital. In the experimental group, male patients will be given violence against women training supported by creative drama five days a day. It will be used as an improved scale-measuring tool for women before and after the training. In the control group, the trainings applied in the service operation will be applied. It will be used as an improved scale-measuring tool for women before and after the training.

Study Type

Interventional

Enrollment (Anticipated)

40

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

  • Turkey
      • Bolu, Turkey, 14100
        • Recruiting
        • Mental Health and Diseases Hospital
        • Contact:
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

14 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Male

Description

Inclusion Criteria:

  • Literate,
  • Male inclusion,
  • Have reached the age of 18,
  • do not have an acute psychotic illness,
  • Patients without symptoms of delirium tremens or intense withdrawal made up the study group of this study.

Exclusion Criteria:

  • Illiterate,Woman,
  • Have an acute psychotic illness,
  • Delirium tremens or those with symptoms of intense withdrawal,
  • Patients who did not agree to participate in the study were not included in this study.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Male patients with a diagnosis of alcohol and substance abuse
Other: Violence against women education supported by creative drama
Violence against women supported by creative drama training will be applied to male patients diagnosed with addiction every day for 5 days.
Other: Routine service operation
Male patients with a diagnosis of alcohol and substance abuse
Other: Routine service operation
No additional training will be applied to the control group and SAMBA trainings in the service operation will be applied.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Pretest final test scores on violence against women
Time Frame: 10 day
Developed by Yalçın Kanbay in 2016, it is a 5-piece Likert type measurement tool consisting of two factors and 30 items. The scale has two sub-dimensions: "attitudes towards the body" and "attitudes towards identity". The total score of the scale is obtained by collecting the scores from two factors. On the scale, there are five answer options. In the scoring of the scale, each question is scored between 1-5. The high scores indicate that they are against violence against women, while the low scores indicate that they are not against violence against women. From the general scale, the lowest score is 30 and the highest score is 150. Kanbay found the Cronbach α value of the scale 0.86 for the overall scale. It is stated that the scale can be applied to individuals with at least primary school graduation and age between 15-65 years of age.
10 day
Pretest final test scores
Time Frame: 10 days
Developed by Yalçın Kanbay in 2016, it is a 5-piece Likert type measurement tool consisting of two factors and 30 items. The scale has two sub-dimensions: "attitudes towards the body" and "attitudes towards identity". The total score of the scale is obtained by collecting the scores from two factors. On the scale, there are five answer options. In the scoring of the scale, each question is scored between 1-5. The high scores indicate that they are against violence against women, while the low scores indicate that they are not against violence against women. From the general scale, the lowest score is 30 and the highest score is 150. Kanbay found the Cronbach α value of the scale 0.86 for the overall scale. It is stated that the scale can be applied to individuals with at least primary school graduation and age between 15-65 years of age.
10 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Abant Izzet Baysal University

Investigators

  • Principal Investigator: hümeyra Hançer tok, msc, Abant Izzet Baysal University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 1, 2022

Primary Completion (Anticipated)

February 1, 2023

Study Completion (Anticipated)

September 1, 2023

Study Registration Dates

First Submitted

September 27, 2022

First Submitted That Met QC Criteria

October 23, 2022

First Posted (Actual)

October 27, 2022

Study Record Updates

Last Update Posted (Actual)

October 27, 2022

Last Update Submitted That Met QC Criteria

October 23, 2022

Last Verified

October 1, 2022

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • AİBÜ-HEM-HHT-01

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

Yes

IPD Plan Description

WE WILL PREPARE THE STUDY AS A THESIS. THEN WE WILL TURN IT INTO A PUBLICATION IN AN INTERNATIONAL MAGAZINE

IPD Sharing Time Frame

DATA WILL BE COLLECTED FOR 1 MONTH

IPD Sharing Access Criteria

CAN BE CONTACTED THROUGH YÖK-THESIS CENTER

IPD Sharing Supporting Information Type

  • Study Protocol
  • Statistical Analysis Plan (SAP)
  • Informed Consent Form (ICF)
  • Clinical Study Report (CSR)
  • Analytic Code

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Addiction

Clinical Trials on Violence against women education supported by creative drama

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Switzerland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe